Network pharmacology and molecular docking-based analyses to predict the potential mechanism of Huangqin decoction in treating colorectal cancer

doi:10.12998/wjcc.v11.i19.4553

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3500)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

2016

Figures (1-8)

360

Tables (1-3)

263

Sum=2728

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

158

Download

424

Sum=582

Jul 6, 2023 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jul 6, 2023; 11(19): 4553-4566
Published online Jul 6, 2023. doi: 10.12998/wjcc.v11.i19.4553

Full Size Figure Download Figure

Figure 7 The docking model of the key active ingredient tetrahydropalmatine to the target proteins. A: Docking of tetrahydropalmatine to Jun proto-oncogene, AP-1 transcription factor subunit; B: Docking of tetrahydropalmatine to tumor protein p53; C: Docking of tetrahydropalmatine to vascular endothelial growth factor; D: Docking of tetrahydropalmatine to AKT1 serine/threonine kinase 1. JUN: Jun proto-oncogene, AP-1 transcription factor subunit; TP53: Tumor protein p53; VEGFA: Vascular endothelial growth factor; AKT1: AKT serine/threonine kinase 1.

Citation: Li YJ, Tang DX, Yan HT, Yang B, Yang Z, Long FX. Network pharmacology and molecular docking-based analyses to predict the potential mechanism of Huangqin decoction in treating colorectal cancer. World J Clin Cases 2023; 11(19): 4553-4566
URL: https://www.wjgnet.com/2307-8960/full/v11/i19/4553.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i19.4553